0
0
The recent decision by India’s GST Council to slash the Goods and Services Tax (GST) on cancer medicines and other essential drugs is being hailed as a significant advance in the country’s effort to make life-saving treatments more affordable and accessible. The move, welcomed by health professionals and patient advocates alike, stands to ease the financial burden for millions and marks a turning point in public health policy.
Key Developments and Findings
On August 24, 2025, the GST Council announced a reduction in the GST rate for several cancer drugs from 12% to 5%, with certain medications also under consideration to be fully exempted. The affected drugs include high-cost therapies such as Trastuzumab Deruxtecan, Osimertinib, and Durvalumab, routinely used in the treatment of cancers like breast cancer and lung cancer. These changes come after similar measures in the Union Budget, which had previously exempted key cancer drugs from customs duties, further reducing treatment costs.
Expert Commentary
The Indian Medical Association (IMA), the nation’s largest body of doctors, has formally lauded the government’s action, noting that the GST reduction directly alleviates the financial pressure faced by families dealing with cancer and other chronic illnesses. According to Dr. S.P. Agarwal, President of the IMA, “Reducing GST not only lowers out-of-pocket expenses for patients but signals a robust commitment to public health by making essential treatments more accessible”. Independent health policy experts, such as Dr. Rishi Mehra of AIIMS New Delhi, described the move as “a critical support for patients whose treatment regimens often run into lakhs of rupees.”deshsewak+2
Context and Background
GST, introduced in India in 2017, unified the country’s tax structure but placed a significant burden on health-related spending by taxing medicines, equipment, and insurance premiums. Until recently, most cancer medicines attracted a 12% GST, adding substantial cost over and above the already steep prices for treatment. With the price of advanced cancer drugs like Osimertinib crossing ₹3,50,000 per course for some patients, even a modest reduction in GST can result in thousands of rupees in savings. The council’s reforms also follow calls from stakeholders to exempt as many essential drugs as possible and to lower taxes on hospital equipment, health insurance premiums, and beds.
Implications for Public Health
According to government estimates, India records over 1.4 million new cancer cases annually. Medication and treatment costs have long been major hurdles to care. By reducing tax rates, the government aims to:
-
Increase accessibility of high-cost treatments for economically disadvantaged populations.
-
Narrow disparities in cancer outcomes caused by financial barriers.
-
Lower overall healthcare expenditure for families.
Beyond cancer, the council has included medicines for rare diseases among those being considered for GST exemption, potentially benefiting patients with conditions like hemophilia and myelodysplastic syndromes.
Statistical Context
According to data from the Ministry of Health and Family Welfare, cancer drug costs constitute up to 50–60% of total cancer treatment expenses for many households. With over 75% of healthcare spending in India still being out-of-pocket, any reduction in medicine taxes provides direct relief to patients.
Potential Limitations and Counterarguments
While the move has been widely praised, medical advocates caution that GST cuts alone may not be enough. Issues such as drug pricing transparency, the high cost of imported medicines, and persistent procedural hurdles for GST registrations faced by hospitals and local clinics remain. Experts also highlight that hospital stays, surgical procedures, and diagnostics still attract different GST rates, affecting affordability. The IMA has called for further exemptions on health insurance premiums and even hospital beds, arguing that a comprehensive approach to tax reform is necessary to truly transform access to care.
Some critics argue that while tax cuts can drive down prices, the benefit must be passed on to patients transparently. Monitoring and enforcement to ensure manufacturers do not absorb the savings is crucial.
Practical Advice for Patients and Healthcare Providers
For patients undergoing treatment or those about to begin costly regimens, the new GST rates mean potential savings on their healthcare bills. Hospitals and pharmacies should update their pricing structures to reflect the new rates. Physicians are encouraged to inform patients about these financial reliefs when discussing treatment options.
Health insurance buyers should stay tuned for further announcements, as the GST Council is actively considering lower taxes on medical and health insurance policies—a measure that can boost coverage and reduce financial distress, especially in emergencies.
Conclusion
The GST Council’s decision to lower taxes on cancer and essential drugs marks an important step towards a more inclusive healthcare system. However, sustained progress will require ongoing attention to drug pricing, insurance coverage, and broader tax rationalization across healthcare services. As India moves forward, collaboration between policy makers, clinicians, and patient groups will be key to ensuring that financial barriers to care continue to fall.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
